Nasdaq delisting risk
The company received notice that its Class A common stock fell below the minimum bid price requirement.
- Scope
- Could reduce liquidity and impair access to capital or strategic transactions.
- Materiality
- high
Hyperfine, Inc.
Hyperfine, Inc. designs and commercializes the Swoop® portable MRI system, a low-field brain imaging platform used in hospitals and other care settings. The company combines hardware, software, and AI/cloud-enabled features to expand access to brain imaging beyond traditional MRI suites and into more decentralized clinical workflows.
−265,4 %
49,8 %
−262,3 %
+5,2 %
4.34
3.73
| % | |
|---|---|
| MRI device sales | 71% Sales of the Swoop® system and related hardware to healthcare providers. |
| Service revenue | 29% Support, maintenance, and related services for installed systems. |
Hyperfine sells primarily to hospitals and hospital systems that want brain imaging at the point of care, especially in...
- U.S. hospitals and hospital systemsprimary
Buy Swoop® systems for inpatient and critical-care brain imaging and to improve access without a traditional MRI suite.
- Emergency departmentssecondary
Use the portable system for rapid neuro assessment and triage when speed and bedside access matter.
- Hospital-based neurology clinicssecondary
Buy the system to support routine neurological imaging in a more flexible outpatient-like setting.
- Neurology officesemerging
Adopt the platform for outside-the-hospital imaging use cases as commercialization broadens.
- International healthcare providersemerging
Purchase the system in markets where regulatory approvals now allow commercialization and MRI penetration is lower.
Revenue is generated in the United States and in selected international markets. The company has begun...
- •United States is the core commercial market and initial launch base
- •Canada is an early international market with Health Canada authorization
- •Europe is expanding after CE Mark and UKCA approvals
- •Australia and New Zealand are approved commercialization markets
- •International growth targets regions with low MRI penetration
Hyperfine is focused on expanding adoption of the Swoop® system through direct U.S. sales coverage, broader clinical...
01
Broaden U.S. clinical use casesshort-term
Expands the addressable market beyond initial critical-care customers and increases system utilization.
02
Expand international commercializationmedium-term
Regulatory approvals in Canada, Europe, Australia, and New Zealand create new growth channels.
03
Advance AI and cloud-enabled product capabilitiesmedium-term
Software enhancements can improve product differentiation and support a higher-value clinical workflow offering.
Hyperfine remains exposed to commercialization risk because adoption depends on convincing hospitals to change imaging...
Commercial adoption risk
Revenue depends on hospitals and clinics adopting a new portable MRI workflow and sustaining utilization.
- Scope
- Slower-than-expected system placements or usage would pressure revenue growth.
- Materiality
- high
Financing and liquidity risk
The company states that access to capital is not assured and may be needed to fund operations and expansion.
- Scope
- Could force delays or reductions in product development and commercialization.
- Materiality
- high
Regulatory and market-access risk
Commercialization in each geography depends on device clearances and local approvals.
- Scope
- Delays or restrictions could slow international revenue expansion.
- Materiality
- medium
Revenue recognition by product and service type
Can create volatility in reported revenue and gross margin mix
Going-concern and liquidity assessment
Affects disclosure, investor perception, and financing assumptions
Equity issuance and warrant accounting
Impacts share count, capital structure, and potentially fair value measurements
Estimates and judgments in development-stage operations
Can materially affect reported operating results and asset valuations
: 28.4.2026